// App-Quantinova.ai

1049 : Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance).

Researchers

Presenter

  • Mark Jesus Mendoza Magbanua

Principal Investigators

  • Oleksandr Oleksandr Savenkov

  • Erik Asmus

  • Karla V. Ballman

  • Janet H Scott

  • John Park

  • Maura N. Dickler

  • Ann H. Partridge

  • Lisa A. Carey

  • Eric P. Winer

  • Hope S. Rugo

Medical Centers

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Weill Cornell Medical College of Cornell University, New York, NY

  • Mayo Clinic, Rochester, MN

  • Weill Cornell Medicine, New York, NY

  • University of California, San Francisco, San Francisco, CA

  • University of California, San Francisco, San Francisco, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Dana-Farber Cancer Institute, Boston, MA

  • University of North Carolina, Chapel Hill, NC

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Bevacizumab

  • Letrozole

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00601900

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved